Last reviewed · How we verify
H. pylori vaccine
This vaccine stimulates the immune system to recognize and eliminate Helicobacter pylori bacteria, preventing infection and associated gastric diseases.
This vaccine stimulates the immune system to recognize and eliminate Helicobacter pylori bacteria, preventing infection and associated gastric diseases. Used for Prevention of Helicobacter pylori infection, Prevention of H. pylori-associated peptic ulcer disease and gastric cancer.
At a glance
| Generic name | H. pylori vaccine |
|---|---|
| Also known as | Oral Recombinant Helicobacter Pylori Vaccine |
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The H. pylori vaccine works by presenting bacterial antigens to the immune system, triggering both humoral and cellular immune responses that generate antibodies and T-cell mediated immunity against H. pylori. This approach aims to prevent initial infection or reduce bacterial colonization in the stomach, thereby preventing peptic ulcer disease, chronic gastritis, and gastric cancer associated with H. pylori infection.
Approved indications
- Prevention of Helicobacter pylori infection
- Prevention of H. pylori-associated peptic ulcer disease and gastric cancer
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Fatigue
- Gastrointestinal symptoms
Key clinical trials
- A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer (PHASE1)
- Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (PHASE1, PHASE2)
- Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults (PHASE1)
- Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults (PHASE1)
- Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers (PHASE1)
- Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults (PHASE1)
- A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children (PHASE3)
- Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H. pylori vaccine CI brief — competitive landscape report
- H. pylori vaccine updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI